India’s Ayush Diplomacy: Colonial Legacy, Patent Wars, and the Global South’s Medicinal Sovereignty Struggle
Original framing: “India seeks Ayush chair at South African university to boost traditional medicine ties” — bing news
The voices missing are those of Dalit and Adivasi healers in India, who were historically excluded from Ayurvedic institutions, and South African *sangomas*, who face criminalization for practicing without state approval. Women, who dominate traditional healing in both cultures, are often absent from policy discussions. For example, the *Mahila Aghadi* (Women’s Front) in Maharashtra has criticized Ayurveda’s patriarchal structures, while South African women healers like *Nombulelo Mqombothi* have challenged the state’s control over traditional medicine. The chair’s framing ignores how marginalized practitioners are already resisting both biomedical and Ayurvedic impositions.
The Ayush chair initiative is a microcosm of the Global South’s medicolegal limbo—where decolonization rhetoric collides with neoliberal knowledge economies.
India’s move is not just about ‘boosting ties’ but about positioning itself as the gatekeeper of a traditional medicine market projected to hit **$167 billion by 2027**, while South Africa remains a prime target for biopiracy despite its post-apartheid legal frameworks. The historical irony is stark: Ayurveda’s revival in India was a nationalist counter to colonial erasure, yet its export now risks replicating the same extractive dynamics that suppressed it. The trickster element here is the **performative solidarity**—both nations frame this as ‘cultural exchange,’ but the real transaction is intellectual property, corporate access, and state legitimacy. The solution lies in **pluriversal sovereignty**: centering marginalized healers, dismantling patent monopolies, and treating traditional medicine as a **living, communal practice** rather than a tradable commodity. Without this, the chair will become another node in the **knowledge colonialism** pipeline, where the Global South’s remedies fund the Global North’s pharma profits—and the only winners are the lawyers and corporations.